New York-based weight management company WW International, Inc. (NASDAQ: WW) announced on Friday the introduction of WeightWatchers RxFlexFund, a programme pairing direct manufacturer pricing for GLP-1 medications with employer subsidy contributions and WeightWatchers' clinical and behavioural services.

Under the cost-sharing model, employers pay for WeightWatchers Clinic access and contribute a configurable percentage of medication costs, between 25% and 75%, while gaining access to transparent manufacturer pricing.

Members gain access to FDA-approved GLP-1 prescriptions and refills through WeightWatchers Clinic under the supervision of obesity-trained clinicians, along with the company's behaviour-change programme, nutritional guidance, and support from registered dietitians and fitness experts.

WeightWatchers said the integrated approach aims to improve adherence, reduce side effects and deliver measurable clinical results while offering employers predictable cost exposure.

The company cited evidence that weight loss among people with chronic conditions can lower annual healthcare expenses. WeightWatchers data shows a 20% reduction in annual healthcare costs when individuals with chronic conditions lose weight, while clinical trials from its Clinic program report a 46% improvement in work-related quality of life.